Craneware has stated that it is "disappointed" with its expected full-year results after it announced that its financial performance is set to be below expectations.

In the year to 30 June, the healthcare financial performance solutions firm said it anticipates revenue to land between $205m and $208m, while earnings are set to reach between $65m and $67m, both broadly in line with the previous financial year.

It said the change results from the timing of “eligible 340B” drugs and the deferral of a small number of significant enterprise contracts, which are now expected to contribute during the 2027 financial year.

While Craneware stated that its customer retention, demand and cash flow had remained strong throughout the year, trading in the final weeks of its full financial year was “materially impacted by a slower than anticipated 340B opportunities into recognised revenue”.

It added that the financial impact of this has reduced conversion once the amount of 340B drugs being shipped to hospitals was realised.

The board believes that these factors reflect a short-term timing impact on its 2026 financial year results, and looking ahead, it said its customer demand is increasingly extending beyond software and analytics towards technology-enabled operational transformation that helps healthcare providers realise the opportunities identified in the firm’s platform.

However, following the announcement, shares in Craneware dropped by almost 19%.

The firm will provide its full-year results in September.

CEO at Craneware, Keith Neilson, concluded: "Naturally we are disappointed not to have delivered the growth that we expected in FY26. While the short-term complexity in the pharmacy market has impacted the year, the long-term opportunity remains intact.

"This reinforces our strategy of expanding beyond software and analytics into technology-enabled operational transformation that helps customers realise the opportunities identified by the group's platform, and this is a continuing area of focus for our innovation efforts. We believe this strengthens both our customer relationships and our long-term growth opportunity, as healthcare providers increasingly seek trusted partners capable of combining data, workflow automation and operational expertise to deliver measurable financial outcomes. Our role is evolving from helping customers identify opportunity to helping them realise it.

"We continue to benefit from high levels of customer retention and cash generation, providing us with a strong financial foundation to execute on our strategy."

---